Top Authors

• Most frequent coverage on TEVA

• 
  Mike Havrilla (1882 followers)

  • A 130 / 30 Global Pharma Strategy (Thu, Nov 5)
  • BioMed News Bytes: Arena, Momenta, Vivus (Sun, Sep 20)
  • 10 New Stock Indexes for Tracking Healthcare Trends (Sun, Jun 28)

  More by Mike Havrilla on TEVA »
• 
  Aaron F. Barkoff (10 followers)

  • Supreme Court Denies Aventis' Cert Petition in Lovenox Case (Wed, Apr 29)
  • Federal Circuit Affirms Extension of Stay Against Teva's Generic Evista (Wed, Feb 25)
  • Eisai Victorious Over Teva and Dr. Reddy’s in Aciphex Compound Patent Case (Wed, Jul 23)

  More by Aaron F. Barkoff on TEVA »
• 
  Shlomo Greenberg (11 followers)

  • Analysts Catching On Only Now, But Teva Has Always Been Heading North (Thu, May 10)
  • Protalix BioTherapeutics: This Dream Could Take Time to Manifest (Fri, Apr 13)
  • Teva: Making a Foray into Biogenerics? (Thu, Mar 22)

  More by Shlomo Greenberg on TEVA »

• Most followed authors on TEVA

• 
  TraderMark (3466 followers)

  • 80 Winning Stocks That Have Nothing to Do with Gold (Fri, Feb 27)

  More by TraderMark on TEVA »
• 
  Bespoke Investment Group (3387 followers)

  • Lowest P/E Ratios in the Nasdaq 100 (Tue, Jun 17)
  • Bill and Melinda Gates Foundation Holdings Outperforming S&P 500 Handily (Tue, Feb 26)

  More by Bespoke Investment Group on TEVA »
• 
  Don Dion (2736 followers)

  • Is IBB the Best Biotech ETF? (Thu, Jul 2)
  • EIS: Israel's Stock Market and Its Emerging Diversification (Wed, Mar 4)
  • IBB: Newfound Stability Lures Biotech Investors (Wed, Feb 18)

  More by Don Dion on TEVA »

• Newest authors on TEVA

• 
  R. Saito (25 followers)

  • Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza (Mon, Nov 16)

  More by R. Saito on TEVA »
• 
  Sara Nunnally (7 followers)

  • The Annihilation of American Automakers: How to Take Advantage of This Trend (Mon, Aug 24)

  More by Sara Nunnally on TEVA »
• 
  BioPharma Investor (71 followers)

  • Mylan: Generic Drugmaker with a Strong Portfolio (Fri, Aug 28)
  • Protalix Biotherapeutics: FDA Fast Track for Gaucher Treatment (Wed, Aug 26)

  More by BioPharma Investor on TEVA »

• Most commented on TEVA

• 
  Chuck Carnevale (212 followers)

  • Why a Market Crash Doesn’t Matter (Sun, Nov 22)
  • Teva Pharmaceutical: Predictable Growth, Good Value (Thu, Aug 20)

  More by Chuck Carnevale on TEVA »
• 
  SA Editor Eli Hoffmann (976 followers)

  • Wall Street Breakfast: Must-Know News (Tue, Nov 3)
  • Wall Street Breakfast: Must-Know News (Thu, Nov 6)
  • Wall Street Breakfast: Must-Know News (Tue, Jul 29)

  More by SA Editor Eli Hoffmann on TEVA »
• 
  SA Editor Rachael Granby (2016 followers)

  • Wall Street Breakfast: Must-Know News (Tue, Jul 28)
  • Wall Street Breakfast: Must-Know News (Tue, May 5)
  • Wall Street Breakfast: Must-Know News (Tue, Feb 17)

  More by SA Editor Rachael Granby on TEVA »